

March 1, 2023

Fourth Quarter 2022 Financial Results

Welcome and Participants

Dr. Jeffrey Graves

President & Chief Executive Officer

Michael Turner

Executive Vice President & Chief Financial Officer

Andrew Johnson

Executive Vice President & Chief Legal Officer

Russell Johnson

Vice President, Treasury & Investor Relations



To participate via phone,
please dial:

1-201-689-8345

Forward Looking Statements


Certain statements made in this presentation that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law

Further, we encourage you to review “Risk Factors” in Part 1 of our Annual Report on Form 10-K and Part II of our Quarterly Reports on Form 10-Q filed with the SEC as well as other information about us in our filings with the SEC. These are available at www.SEC.gov.



Dr. Jeffrey Graves

President & Chief Executive Officer



2022 Highlights



- **Challenging** 2022 business environment
 - Macroeconomic and geopolitical headwinds
 - Softer dental market demand due to inflationary pressure on elective procedures
- Pivoted in second half of year to finish **near revised guidance**
 - Efficiency gains from manufacturing in-sourcing
- 2022 was year of **strategic investment**
 - Platform refreshes
 - Technology acquisitions
 - Regenerative medicine
- Business **well positioned** for continued growth

New Hardware Platforms Driving Growth

SLA 750 & SLA 750 Dual

- **April 2022** – 3D Systems launches new SLA 750
- **Feb 2023** – BWT Alpine F1 acquires four SLA 750s



MJP 2500W Plus

- **Feb 2023** – 3D Systems launches MJP 2500W Plus

Next-generation printer
for higher throughput, higher resolution
jewelry wax casting patterns



Accelerating Innovation through Acquired Technology



University Hospital Salzburg
Salzburg, Austria - February 2023

1st clinical implantation of PEEK cranial device printed on a Kumovis printer



Investing in Regenerative Medicine

3D Systems Bioprinting Leadership



35+ Years of developing
advanced 3D printing
applications



Organ development
partnership since 2017




Acquired in 2021 to expand
bioprinting capabilities

Human Organs



**Most Complex Object
Ever 3D Printed**


3D printed
human lung scaffold



- ✓ 2 Lobes
- ✓ 5,000 kilometers of vasculature
- ✓ 213 Million Alveoli
- ✓ 44 Trillion Voxels

Regenerative Tissue Program

**Vascularized Breast Tissue Scaffold
for Implantation & Cellularization**




Drug Development



Bioprinted "Organ-on-a-chip"

can accurately replicate organ-specific drug response in pre-clinical drug trials



h-VIOS₂ chip
with perfused vasculature



2023 Priorities

- ✓ Harvest benefits of technology platform investments
- ✓ Invest in regenerative medicine for future growth
- ✓ Continue to optimize manufacturing footprint
- ✓ Organization-wide focus on cost synergies & operational excellence
- ✓ Break Even to Positive Adjusted EBITDA and FCF



Michael Turner

Chief Financial Officer



Q4 & FY 2022 Revenue Summary

Full Year 2022

- FY 2022 revenue - **\$538.0 million**
- 12.6% decrease vs. FY 2021
- 3.3% increase vs. FY 2021 excluding divestitures and in constant currency

Fourth Quarter 2022

- Q4 2022 revenue - **\$132.7 million**
- 12.0% decrease vs. Q4 2021
- 7.6% decrease vs. Q4 2021 in constant currency

- Divestiture Impact
- Significant FX headwinds
- Russia exit reduced FY 2022 results
- Dental market softness significantly impacted Q4 and FY 2022 results

Balance of business is well-positioned with solid demand and growth trends

* see Appendix for reconciliation of revenue adjusted for divestitures and revenue adjusted for divestitures and in constant currency




Revenue by Segment


(\$ millions except percentages)

Healthcare
Solutions



Full Year ¹



Fourth Quarter



Industrial
Solutions



¹ Adjusted for
2021 divestitures

*Healthcare down 2.9% Constant Currency
Industrial up 9.7% Constant Currency*


*Healthcare down 16.6% Constant Currency
Industrial up 1.1% Constant Currency*

* see Appendix for reconciliation of revenue adjusted for divestitures and revenue in constant currency



Gross Profit Margin

(non-GAAP)



FY 2022 vs. FY 2021

- FY 2022 GM% of **39.8%** vs. FY 2021 **42.5%**
- Impacted by divestitures, inflation, freight, and mix

Q4 2022 vs. Q4 2021

- Q4 2022 GM% of **40.9%** vs. Q4 2021 **44.1%**
- Impacted by divestitures, inflation, freight, and mix


Sequential Improvement Q2 → Q4

- Focus on operational excellence, including continued benefits from Q3 2022 in-sourcing actions



Non-GAAP Operating Expenses

(Non-GAAP excluding Divestitures - \$ millions)



FY 2022 vs. FY 2021

- Non-GAAP opex of \$241.1 million
- 22.1% increase vs. FY 2021
- Acquisition opex
- Increased R&D to enhance product portfolio and build regenerative medicine business
- Investing in corporate infrastructure

Q4 2022 vs. Q4 2021


- Non-GAAP opex of \$64.1 million
- 18.2% increase vs. Q4 2021
- Same drivers as Full Year

See appendix for a reconciliation of non-GAAP operating expenses excluding divestitures.



Adjusted EBITDA & Adjusted EBITDA Margin %

(Excluding Divestitures - \$ millions)



FY 2022 Adjusted EBITDA - (\$5.8) million
Q4 2022 Adjusted EBITDA - (\$4.8) million

- Impact from acquired businesses, most of which are in development stage or early commercialization
- Investments in R&D and infrastructure

Adj. EBITDA Margin % is defined as non-GAAP Operating Income excluding divestitures plus Depreciation divided by Revenue

See appendix for a reconciliation of non-GAAP Operating Income and Adjusted EBITDA.





Strong Balance Sheet

- Ended the quarter with \$568.7 million dollars of cash and short-term investments
- We have sufficient cash to support organic growth, including in regenerative medicine
- Invested \$104.3 million in acquisitions and investments in FY 2022
- Current focus is on operational execution and integration of recent acquisitions

Financial Guidance

Full Year 2023 Guidance	
Revenue	\$545 – \$575 million
Non-GAAP Gross Margin	40% – 42%
Adjusted EBITDA	Break even or better
Free Cash Flow	Break even or better

Comments

- **4% revenue growth (midpoint)**
- **Mid-teens revenue growth ex-dental**
- **Reflects**
 - YoY decline in dental revenue
 - YoY increase in investment spending for regenerative medicine
- **Adjusted EBITDA and Free Cash Flow do not include restructuring costs**
- **Free Cash Flow defined as:**
Adj. EBITDA less Δ WC less capex





Q&A Session

1-201-689-8345



Thank You

Find out more at:

www.3dsystems.com



Appendix

Presentation of Information

3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain non-GAAP measures, including: non-GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX effects), non-GAAP Gross profit, non-GAAP Gross profit margin, non-GAAP Operating expenses, non-GAAP Operating (loss)/income, non-GAAP Interest and other income/(expense), net, non-GAAP Net income (loss), non-GAAP Basic and Diluted Income (Loss) per Share, adjusted EBITDA and adjusted EBITDA Margin. These non-GAAP measures exclude certain special items that management does not view as part of 3D Systems' underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Management believes that the non-GAAP measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of period-over-period results. Additionally, management uses the non-GAAP measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. 3D Systems' non-GAAP measures are not calculated in accordance with or as required by GAAP and may not be calculated the same as similarly titled measures used by other companies. These non-GAAP measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.

A reconciliation of GAAP to non-GAAP financial measures is provided in the accompanying schedules in the Appendix.

3D Systems does not provide forward-looking guidance for certain measures on a GAAP basis. The company is unable to provide a quantitative reconciliation of forward-looking non-GAAP gross profit margins and non-GAAP operating expenses to the most directly comparable forward-looking GAAP measures without unreasonable effort because certain items, including legal, acquisition expenses, stock-compensation expense, intangible amortization expense, restructuring expenses, and goodwill impairment, are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

Non-GAAP Reconciliation – Quarter Ended Dec. 31, 2021

(Unaudited)

<i>(in millions, except per share data)</i>	Three Months Ended December 31,							
	2021				2021			
	GAAP	Amortization, stock-based compensation & other	Legal, acquisition and divestiture - related ⁽¹⁾	Cost optimization plan	Product end of life adjustment	Divestitures	Non-GAAP	
Revenue	\$ 150.9	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 150.9	
Gross Profit	66.2	0.2	—	—	0.2	—	66.6	
Gross Profit Margin	43.9 %						44.1 %	
Operating expenses	70.1	(13.2)	(1.1)	(1.5)	—	—	54.3	
Operating income (loss)	(3.8)	13.4	1.1	1.5	0.2	—	12.4	
Interest and other income (expense), net	(1.8)	—	1.1	—	—	—	(0.7)	
Net income (loss)	(6.2)	13.4	2.7	1.5	0.2	—	11.6	
Net income (loss) EPS - basic	(0.05)	0.11	0.02	0.01	—	—	0.09	
Net income (loss) EPS - diluted	\$ (0.05)	\$ 0.10	\$ 0.02	\$ 0.01	\$ —	\$ —	\$ 0.09	
Weighted Average Shares - basic	124.9						124.9	
Weighted Average Shares - diluted	127.9						127.9	

⁽¹⁾Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

Non-GAAP Reconciliation – Quarter Ended March 31, 2022

(Unaudited)

(in millions, except per share data)

Three Months Ended March 31, 2022, ⁽¹⁾

	GAAP	Amortization, stock-based compensation & other	Legal, acquisition and divestiture - related	Non-GAAP
Revenue	\$ 133.0	\$ —		\$ 133.0
Gross Profit	53.8	0.1		53.9
Gross Profit Margin	40.4%			40.6%
Operating expenses	77.0	(15.2)	(4.0)	57.8
Operating (loss) income	(23.2)	15.3	4.0	(3.9)
Interest and other income (expense), net	(2.3)	—	0.3	(2.0)
Net (loss) income	(26.8)	15.3	4.3	(7.2)
Diluted (loss) income per share	\$ (0.21)	\$ 0.12	\$ 0.03	\$ (0.06)
Diluted shares outstanding	126.7			126.7

⁽¹⁾Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

Non-GAAP Reconciliation – Quarter Ended June 30, 2022

(Unaudited)

(in millions, except per share data)

Three Months Ended June 30, 2022, ⁽¹⁾

	GAAP	Amortization, stock-based compensation & other	Legal, acquisition and divestiture - related ⁽²⁾	Non-GAAP
Revenue	\$ 140.0	\$ —	\$ —	\$ 140.0
Gross Profit	53.1	0.1	—	53.3
Gross Profit Margin	37.9%			38.1%
Operating expenses	85.2	(12.6)	(11.7)	60.9
Operating (loss) income	(32.0)	12.7	11.7	(7.6)
Interest and other income (expense), net	0.3	—	0.1	0.4
Net (loss) income	(33.0)	12.7	11.8	(8.5)
Diluted (loss) income per share	\$ (0.26)	\$ 0.10	\$ 0.09	\$ (0.07)
Diluted shares outstanding	127.7			127.7

⁽¹⁾Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

⁽²⁾ Included are \$11.0 million of estimated costs for legal and other settlements

Non-GAAP Reconciliation – Quarter Ended Sept. 30, 2022

(Unaudited)

(in millions, except per share data)

Three Months Ended September 30, 2022, ⁽¹⁾

	GAAP	Amortization, stock-based compensation & other	Legal, acquisition and divestiture - related ⁽²⁾	Cost optimization plan ⁽²⁾	Impairment of cost-method investments	Non-GAAP
Revenue	\$ 132.3	—	—	\$ —	\$ —	\$ 132.3
Gross Profit	52.7	0.2	—	—	—	52.8
Gross Profit Margin	39.8%					39.9%
Operating expenses	86.4	(17.6)	(10.2)	(0.3)	—	58.3
Operating (loss) income	(33.7)	17.8	10.2	0.3	—	(5.5)
Interest and other income (expense), net	(3.5)	—	—	—	2.9	(0.6)
Net (loss) income attributable to 3D Systems Corporation	(37.4)	17.8	10.2	0.3	2.9	(6.3)
Basic and diluted net (loss) income per share	\$ (0.30)	\$ 0.14	\$ 0.08	\$ —	\$ 0.02	\$ (0.05)

Basic and diluted shares outstanding

128.0

128.0

⁽¹⁾Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

⁽²⁾Included are \$9.7 million of estimated costs for legal and other settlements

Non-GAAP Reconciliation – Quarter Ended Dec. 31, 2022

(Unaudited)

<i>(in millions, except per share data)</i>	Three Months Ended December 31, ⁽¹⁾						2022
	2022		2022		2022		
	GAAP	Amortization, stock-based compensation & other	Legal, acquisition and divestiture -related	Cost optimization plan	Impairment of cost-method investments	Non-GAAP	
Revenue	\$ 132.7	\$ —	\$ —	\$ —	\$ —	\$ 132.7	
Gross Profit	54.6	(0.4)	—	—	—	54.2	
Gross Profit Margin	41.2%					40.9%	
Operating expenses	82.7	(14.6)	(3.6)	(0.4)	—	64.1	
Operating income (loss)	(28.0)	14.2	3.6	0.4	—	(9.9)	
Interest and other income (expense), net	1.7	—	(0.1)	—	—	1.6	
Net income (loss)	(25.6)	14.2	3.5	0.4	—	(7.5)	
Net income (loss) EPS - basic	(0.20)	0.11	0.03	—	—	(0.06)	
Net income (loss) EPS - diluted	\$ (0.20)	\$ 0.11	\$ 0.03	\$ —	\$ —	\$ (0.06)	
Weighted Average Shares - basic	128.8					128.8	
Weighted Average Shares - diluted	128.8					128.8	

⁽¹⁾Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

Non-GAAP Operating Income to Adjusted EBITDA Reconciliation

(in Millions, Unaudited)

<i>(in millions)</i>	<u>Q4-2021</u>	<u>Q1-2022</u>	<u>Q2-2022</u>	<u>Q3-2022</u>	<u>Q4-2022</u>
Revenue - 2021 excludes revenue from divestiture	\$ 150.9	\$ 133.0	\$ 140.0	\$ 132.3	\$ 132.7
Non-GAAP Operating (loss) income	12.3	(3.9)	(7.6)	(5.5)	(9.9)
Depreciation	5.6	5.8	5.0	5.2	5.1
Adjusted EBITDA	\$ 17.9	\$ 1.9	\$ (2.6)	\$ (0.3)	\$ (4.8)
Adjusted EBITDA Margin	11.9%	1.4%	(1.9)%	(0.2)%	(3.6)%

⁽¹⁾ Amounts in table may not foot due to rounding and percent changes have been calculated based on rounded amounts.

Reconciliation of Revenue to Non-GAAP Revenue⁽¹⁾ (in Millions, Unaudited)

<i>(in millions)</i>	Three Months Ended		% Change	Constant Currency ⁽²⁾	
	December 31, 2022	December 31, 2021		FX Effect ⁽³⁾	B(W)%
Revenue, as reported					
Healthcare	\$ 60.7	\$ 74.5	(18.5)%		
Industrial	72.0	76.4	(5.7)%		
Total Revenue, as reported	\$ 132.7	\$ 150.9	(12.0)%		
Revenue From Divestitures:					
Healthcare	\$ —	\$ —			
Industrial	—	—			
Total Revenue	\$ —	\$ —			
Total Revenue (Excl. Divest. and FX Effect):					
Healthcare	\$ 60.7	\$ 74.5	(18.5)%	\$ (1.4)	(16.6)%
Industrial	72.0	76.4	(5.7)%	(5.2)	1.1 %
Total Revenue (Excl. Divest. and FX Effect):	\$ 132.7	\$ 150.9	(12.0)%	\$ (6.6)	(7.6)%

⁽¹⁾ Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

⁽²⁾ To assist in the analysis of the company's revenue trends, the company estimated the impact of foreign exchange on year over year revenue growth by recasting revenue, excluding divestitures, for the three months and year ended December 31, 2022 by applying the foreign exchange rates used to translate 2021 non-US functional currency revenue to 2022 non-US functional currency revenue.

⁽³⁾ FX effect is the estimated impact on "as reported" net revenue due to changes in foreign currency exchange rates

Reconciliation of Revenue to Non-GAAP Revenue⁽¹⁾ (in Millions, Unaudited)

<i>(in millions)</i>	Year Ended December 31, 2022	Year Ended December 31, 2021	% Change	Constant Currency ⁽²⁾	
				FX Effect ⁽³⁾	B(W)%
Revenue, as reported					
Healthcare	\$ 261.0	\$ 306.2	(14.8) %		
Industrial	277.0	309.5	(10.5) %		
Total Revenue, as reported	\$ 538.0	\$ 615.7	(12.6) %		
Revenue From Divestitures:					
Healthcare	\$ —	\$ 31.8			
Industrial		39.9			
Total Revenue	\$ —	\$ 71.7			
Total Revenue (Excl. Divest. and FX Effect):					
Healthcare	\$ 261.0	\$ 274.4	(4.9) %	\$ (5.6)	(2.9) %
Industrial	277.0	269.6	2.8 %	(18.6)	9.7 %
Total Revenue (Excl. Divest. and FX Effect):	\$ 538.0	\$ 544.0	(1.1) %	\$ (24.2)	3.3 %

⁽¹⁾ Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts

⁽²⁾ To assist in the analysis of the company's revenue trends, the company estimated the impact of foreign exchange on year over year revenue growth by recasting revenue, excluding divestitures, for the three months and year ended December 31, 2022 by applying the foreign exchange rates used to translate 2021 non-US functional currency revenue to 2022 non-US functional currency revenue.

⁽³⁾ FX effect is the estimated impact on "as reported" net revenue due to changes in foreign currency exchange rates